The FINANCIAL -- People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response, according to University of Pennsylvania.…
Read More »
